PMID- 28272707
OWN - NLM
STAT- MEDLINE
DCOM- 20170731
LR  - 20220321
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 21
IP  - 4
DP  - 2017 Feb
TI  - Reduced miR-300 expression predicts poor prognosis in patients with laryngeal 
      squamous cell carcinoma.
PG  - 760-764
LID - 12240 [pii]
AB  - OBJECTIVE: miR-300 has been demonstrated to play an important role in the 
      progression of several tumors, but its role in tumorigenesis of laryngeal 
      squamous cell carcinoma (LSCC) is still unclear. The purpose of this study was to 
      explore miR-300 expression in LSCC patients and analyze its association with 
      clinicopathological factors and prognosis. PATIENTS AND METHODS: In the present 
      study, we measured the expression level of miR-300 in LSCC tissues by RT-PCR. 
      Associations between miRNA-300 expressions and various clinicopathological 
      characteristics were analyzed. Patient survival and their differences were 
      determined by Kaplan-Meier method and log-rank test. The univariate and 
      multivariate analysis were performed using the Cox proportional hazard analysis. 
      RESULTS: miR-300 expression was significantly increased in LSCC tissues compared 
      with that in adjacent non-cancerous tissues (p < 0.01). In addition, lymph node 
      metastasis (p = 0.004) and TNM stage (p = 0.001) were obvious influence factors 
      for the expression of miR-300. More importantly, Kaplan-Meier analysis showed 
      that LSCC patients with low miR-300 expression tended to have shorter overall 
      survival (p < 0.001). Finally, multivariate analysis revealed that miR-300 
      expression was an independent prognostic factor for LSCC patients. CONCLUSIONS: 
      Our results pointed to miR-300 as a powerful prognostic marker in LSCC and as a 
      novel target for tumor-suppressive therapy.
FAU - He, F-Y
AU  - He FY
AD  - Department of Ear-nose-throat (ENT), Yidu Central Hospital of Weifang, Qingzhou, 
      Shandong, China. sjj_0sj@yeah.net.
FAU - Liu, H-J
AU  - Liu HJ
FAU - Guo, Q
AU  - Guo Q
FAU - Sheng, J-L
AU  - Sheng JL
LA  - eng
PT  - Journal Article
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (MIRN300 microRNA, human)
RN  - 0 (MicroRNAs)
SB  - IM
MH  - Aged
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Squamous Cell/diagnosis/*metabolism
MH  - Female
MH  - Humans
MH  - Laryngeal Neoplasms/diagnosis/*metabolism
MH  - Male
MH  - MicroRNAs/*metabolism
MH  - Middle Aged
MH  - Prognosis
EDAT- 2017/03/09 06:00
MHDA- 2017/08/02 06:00
CRDT- 2017/03/09 06:00
PHST- 2017/03/09 06:00 [entrez]
PHST- 2017/03/09 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
AID - 12240 [pii]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2017 Feb;21(4):760-764.